{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  St John's Wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  aceclofenac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"agomelatine\" outputclass=\"int-drug\">agomelatine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  agomelatine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Agomelatine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"alcohol (beverage)\" outputclass=\"int-drug\">alcohol (beverage)</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  alcohol (beverage)  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol (beverage)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"alfentanil\" outputclass=\"int-drug\">alfentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  alfentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"alimemazine\" outputclass=\"int-drug\">alimemazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  alimemazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alimemazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"alprazolam\" outputclass=\"int-drug\">alprazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  alprazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  amifampridine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aminophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  amiodarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  amisulpride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779514_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  amisulpride  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amphotericin\" outputclass=\"int-drug\">Amphotericin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amphotericin   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  anagrelide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779516_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  anagrelide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  apalutamide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  apomorphine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  apraclonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apraclonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  aripiprazole  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aripiprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  arsenic trioxide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  artemether  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  artenimol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"articaine\" outputclass=\"int-drug\">articaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  articaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Articaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  asenapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  aspirin  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  baclofen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baclofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">Bambuterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bambuterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  bedaquiline  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  benperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  bevacizumab  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  bosutinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  brimonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brimonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"buclizine\" outputclass=\"int-drug\">buclizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  buclizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bumetanide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"bupivacaine\" outputclass=\"int-drug\">bupivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  bupivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"buprenorphine\" outputclass=\"int-drug\">buprenorphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  buprenorphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buprenorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"bupropion\" outputclass=\"int-drug\">bupropion</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  bupropion  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"buspirone\" outputclass=\"int-drug\">buspirone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  buspirone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buspirone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cabozantinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cangrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cannabis extract\" outputclass=\"int-drug\">cannabis extract</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cannabis extract  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cannabis extract</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cariprazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  celecoxib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ceritinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"chloral hydrate\" outputclass=\"int-drug\">chloral hydrate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  chloral hydrate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloral hydrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"chlordiazepoxide\" outputclass=\"int-drug\">chlordiazepoxide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  chlordiazepoxide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlordiazepoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"chlorphenamine\" outputclass=\"int-drug\">chlorphenamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  chlorphenamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorphenamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  chlorpromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779558_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  chlorpromazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cilostazol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"cimetidine\" outputclass=\"int-drug\">Cimetidine</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Cimetidine   slightly   increases   the exposure to   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cimetidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cinnarizine\" outputclass=\"int-drug\">cinnarizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cinnarizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinnarizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  citalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779563_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  citalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779563_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  venlafaxine  and  citalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clarithromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779564_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clemastine\" outputclass=\"int-drug\">clemastine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clemastine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clemastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clobazam\" outputclass=\"int-drug\">clobazam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clobazam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clobazam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clomethiazole\" outputclass=\"int-drug\">clomethiazole</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clomethiazole  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomethiazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779568_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  clomipramine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clonazepam\" outputclass=\"int-drug\">clonazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clonazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clopidogrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  clozapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"codeine\" outputclass=\"int-drug\">codeine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  codeine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Codeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  crizotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779576",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779576_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cyclizine\" outputclass=\"int-drug\">cyclizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cyclizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779577",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779577_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">cyproheptadine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  cyproheptadine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779578",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779578_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779579",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779579_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dalteparin   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779580",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779580_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779581",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779581_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dapoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779581_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  dapoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dasatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779583_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  dasatinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  delamanid  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  desflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779588",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779588_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dexibuprofen\" outputclass=\"int-drug\">dexibuprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dexibuprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dexketoprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dexmedetomidine\" outputclass=\"int-drug\">dexmedetomidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dexmedetomidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexmedetomidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"diamorphine\" outputclass=\"int-drug\">diamorphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  diamorphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diamorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"diazepam\" outputclass=\"int-drug\">diazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  diazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  diclofenac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dihydrocodeine\" outputclass=\"int-drug\">dihydrocodeine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dihydrocodeine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dihydrocodeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dipipanone\" outputclass=\"int-drug\">dipipanone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dipipanone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipipanone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dipyridamole  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  disopyramide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disopyramide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"domperidone\" outputclass=\"int-drug\">Domperidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Domperidone   increases   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Domperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">dronedarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  dronedarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  droperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779601_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  droperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779602_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  duloxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  efavirenz  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  encorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enoxaparin   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  epoprostenol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">eptifibatide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  eptifibatide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  eribulin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  erythromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  escitalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779612_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  escitalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779612_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  venlafaxine  and  escitalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  esketamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  etodolac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  etomidate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etomidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  etoricoxib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779617_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  fentanyl  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fingolimod\" outputclass=\"int-drug\">Fingolimod</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fingolimod   increases   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fingolimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  flecainide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  fluconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  fluoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779622_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  fluoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  flupentixol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flupentixol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluphenazine\" outputclass=\"int-drug\">fluphenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  fluphenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779624_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluphenazine\" outputclass=\"int-drug\">fluphenazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  fluphenazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluphenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"flurazepam\" outputclass=\"int-drug\">flurazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  flurazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  flurbiprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779627",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779627_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  fluvoxamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779627_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  fluvoxamine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779628",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779628_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779629",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779629_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"formoterol\" outputclass=\"int-drug\">Formoterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Formoterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779630",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779630_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779631",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779631_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779632",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779632_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Furosemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779633",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779633_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  gabapentin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779634",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779634_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779634_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"granisetron\" outputclass=\"int-drug\">Granisetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Granisetron   is predicted to   increase   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779635",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779635_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  guanfacine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779636",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779636_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  haloperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779636_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  haloperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779636_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">Venlafaxine</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Venlafaxine   slightly   increases   the exposure to   haloperidol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779637",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779637_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">Heparin (unfractionated)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Heparin (unfractionated)   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin (unfractionated)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779638",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779638_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779639",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779639_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779640",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779640_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779641",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779641_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"hydromorphone\" outputclass=\"int-drug\">hydromorphone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  hydromorphone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydromorphone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779642",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779642_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  hydroxyzine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779642_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  hydroxyzine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779643",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779643_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ibrutinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779644",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779644_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ibuprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779645",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779645_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  iloprost  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">Indacaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indacaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  indometacin  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779651",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779651_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  inotersen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  inotuzumab ozogamicin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  isoflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">Ivabradine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivabradine   is predicted to   increase   the risk of torsade de pointes when given with   venlafaxine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivabradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ketamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ketoprofen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779660",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779660_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ketorolac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779661",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779661_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ketotifen\" outputclass=\"int-drug\">ketotifen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ketotifen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779662",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779662_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lamotrigine\" outputclass=\"int-drug\">lamotrigine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lamotrigine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lamotrigine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779663",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779663_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lapatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779664",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779664_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lenvatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779665",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779665_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"levetiracetam\" outputclass=\"int-drug\">levetiracetam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  levetiracetam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levetiracetam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779666",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779666_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  levomepromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779666_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  levomepromazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779667",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779667_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lidocaine\" outputclass=\"int-drug\">lidocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lidocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lidocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779668",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779668_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779669",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779669_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779670",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779670_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779670_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  lithium  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779671",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779671_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lofexidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779671_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  lofexidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779672",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779672_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779673",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779673_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"loprazolam\" outputclass=\"int-drug\">loprazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  loprazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779674",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779674_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lorazepam\" outputclass=\"int-drug\">lorazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lorazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lorazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779675",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779675_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lormetazepam\" outputclass=\"int-drug\">lormetazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lormetazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lormetazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779676",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779676_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  loxapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779677",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779677_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  lurasidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779678",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779678_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  mefenamic acid  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779679",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779679_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefloquine\" outputclass=\"int-drug\">Mefloquine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefloquine   is predicted to   increase   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefloquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779680",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779680_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"melatonin\" outputclass=\"int-drug\">melatonin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  melatonin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melatonin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779681",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779681_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  meloxicam  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779682",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779682_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"mepivacaine\" outputclass=\"int-drug\">mepivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  mepivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mepivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779683",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779683_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"meprobamate\" outputclass=\"int-drug\">meprobamate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  meprobamate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meprobamate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779684",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779684_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"meptazinol\" outputclass=\"int-drug\">meptazinol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  meptazinol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meptazinol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779685",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779685_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779685_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  methadone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779685_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  venlafaxine  and  methadone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779686",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779686_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"methocarbamol\" outputclass=\"int-drug\">methocarbamol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  methocarbamol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methocarbamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779687",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779687_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  methoxyflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxyflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779688",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779688_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779689",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779689_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779690",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779690_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779691",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779691_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  mianserin  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779691_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  mianserin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779692",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779692_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"midazolam\" outputclass=\"int-drug\">midazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  midazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Midazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779693",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779693_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779693_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  mirtazapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779694",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779694_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">Mizolastine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mizolastine   is predicted to   increase   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779695",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779695_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779696",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779696_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"morphine\" outputclass=\"int-drug\">morphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  morphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Morphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779697",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779697_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  moxifloxacin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779698",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779698_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  moxonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779699",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779699_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"nabilone\" outputclass=\"int-drug\">nabilone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  nabilone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabilone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779700",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779700_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  nabumetone  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779701",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779701_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  naproxen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779702",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779702_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779703",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779703_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779704",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779704_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  nilotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779705",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779705_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"nitrazepam\" outputclass=\"int-drug\">nitrazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  nitrazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779706",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779706_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  nitrous oxide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrous oxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779707",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779707_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  olanzapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779708",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779708_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">Olodaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olodaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779709",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779709_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">Omega-3-acid ethyl esters</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Omega-3-acid ethyl esters   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779710",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779710_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779710_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  ondansetron  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779711",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779711_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  osimertinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779712",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779712_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"oxazepam\" outputclass=\"int-drug\">oxazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  oxazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779713",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779713_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"oxycodone\" outputclass=\"int-drug\">oxycodone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  oxycodone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxycodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779714",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779714_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  paliperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779714_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  paliperidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779715",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779715_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779715_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">Palonosetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Palonosetron   is predicted to   increase   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779716",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779716_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  panobinostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779717",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779717_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"papaveretum\" outputclass=\"int-drug\">papaveretum</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  papaveretum  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Papaveretum</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779718",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779718_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  parecoxib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779719",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779719_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  paroxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779719_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  paroxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779720",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779720_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pasireotide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779721",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779721_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pazopanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779722",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779722_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   pentamidine   potentially   increases   the risk of QT-prolongation when given with   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779723",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779723_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779723_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  pentazocine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779724",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779724_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"perampanel\" outputclass=\"int-drug\">perampanel</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  perampanel  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perampanel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779725",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779725_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pericyazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779726",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779726_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779726_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  pethidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779727",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779727_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779728",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779728_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779729",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779729_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">phenobarbital</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  phenobarbital  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779730",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779730_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pimozide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779730_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  pimozide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779731",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779731_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  piroxicam  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779732",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779732_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">Venlafaxine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pitolisant\" outputclass=\"int-drug\">pitolisant</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Venlafaxine   is predicted to   increase   the exposure to   pitolisant .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pitolisant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779733",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779733_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pizotifen\" outputclass=\"int-drug\">pizotifen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pizotifen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pizotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779734",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779734_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  prasugrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779735",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779735_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779736",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779736_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"pregabalin\" outputclass=\"int-drug\">pregabalin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  pregabalin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pregabalin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779737",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779737_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"prilocaine\" outputclass=\"int-drug\">prilocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  prilocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "237",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prilocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779738",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779738_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"primidone\" outputclass=\"int-drug\">primidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  primidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "238",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779739",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779739_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  procarbazine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "239",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779740",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779740_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  prochlorperazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "240",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779741",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779741_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  promazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "241",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779742",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779742_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"promethazine\" outputclass=\"int-drug\">promethazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  promethazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "242",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promethazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779743",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779743_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  propofol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "243",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propofol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779744",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779744_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  quetiapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "244",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779745",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779745_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  quinine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "245",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779746",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779746_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ranolazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "246",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779747",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779747_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "247",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779748",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779748_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  regorafenib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "248",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779749",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779749_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"remifentanil\" outputclass=\"int-drug\">remifentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  remifentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "249",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Remifentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779750",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779750_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ribociclib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "250",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779751",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779751_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  risperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779751_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  risperidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "251",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779752",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779752_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "252",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779753",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779753_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "253",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779754",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779754_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "254",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779755",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779755_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ropivacaine\" outputclass=\"int-drug\">ropivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ropivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "255",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779756",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779756_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "256",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779757",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779757_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">Salbutamol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salbutamol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "257",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779758",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779758_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">Salmeterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salmeterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "258",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779759",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779759_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">saquinavir</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  saquinavir  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779759_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Saquinavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "259",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779760",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779760_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "260",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779761",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779761_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sertraline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779761_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  sertraline  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "261",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779762",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779762_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sevoflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "262",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779763",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779763_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sildenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "263",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779764",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779764_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sodium oxybate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "264",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium oxybate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779765",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779765_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "265",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779766",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779766_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sotalol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "266",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779767",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779767_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "267",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779768",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779768_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sufentanil\" outputclass=\"int-drug\">sufentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sufentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "268",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sufentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779769",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779769_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sulfinpyrazone\" outputclass=\"int-drug\">sulfinpyrazone</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sulfinpyrazone  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "269",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfinpyrazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779770",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779770_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sulindac  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "270",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779771",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779771_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sulpiride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779771_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  sulpiride  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "271",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779772",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779772_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "272",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779773",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779773_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  sunitinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "273",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779774",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779774_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">Tacrolimus</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tacrolimus   potentially   increases   the risk of serotonin syndrome when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "274",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779775",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779775_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tapentadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779775_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  tapentadol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "275",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779776",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779776_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"telavancin\" outputclass=\"int-drug\">telavancin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  telavancin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "276",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telavancin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779777",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779777_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"temazepam\" outputclass=\"int-drug\">temazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  temazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "277",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779778",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779778_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "278",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779779",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779779_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tenoxicam  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "279",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779780",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779780_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">Terbutaline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbutaline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "280",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779781",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779781_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tetrabenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "281",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779782",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779782_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tetracaine\" outputclass=\"int-drug\">tetracaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tetracaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "282",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779783",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779783_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  thalidomide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "283",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779784",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779784_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Theophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "284",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779785",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779785_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  thiopental  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "285",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiopental</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779786",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779786_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tiaprofenic acid  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "286",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779787",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779787_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  ticagrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "287",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779788",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779788_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "288",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779789",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779789_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "289",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779790",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779790_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">tirofiban</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tirofiban  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "290",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779791",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779791_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tizanidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779791_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  tizanidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "291",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779792",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779792_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tolfenamic acid  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "292",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779793",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779793_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tolterodine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "293",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779794",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779794_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Torasemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "294",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779795",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779795_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  toremifene  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "295",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779796",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779796_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779796_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  tramadol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "296",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779797",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779797_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "297",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779798",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779798_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  trastuzumab emtansine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "298",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779799",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779799_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779799_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  trazodone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "299",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779800",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779800_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "300",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779801",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779801_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  trifluoperazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "301",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779802",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779802_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "302",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779803",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779803_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "303",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779804",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779804_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  vandetanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "304",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779805",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779805_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  vardenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "305",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779806",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779806_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  vemurafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "306",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779807",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779807_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">Vilanterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vilanterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "307",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779808",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779808_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  vinflunine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "308",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779809",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779809_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  voriconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779809_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   venlafaxine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "309",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779810",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779810_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779810_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  vortioxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "310",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779811",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779811_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   is predicted to   increase   the risk of bleeding events when given with   venlafaxine .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "311",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779812",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779812_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   venlafaxine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "312",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779813",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779813_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "313",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779814",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779814_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"zolpidem\" outputclass=\"int-drug\">zolpidem</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  zolpidem  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "314",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolpidem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779815",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779815_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"zopiclone\" outputclass=\"int-drug\">zopiclone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  zopiclone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "315",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zopiclone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779816",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779816_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  venlafaxine  and  zuclopenthixol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2#bnf_i1557280779816_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"venlafaxine\" outputclass=\"int-heading-drug\">venlafaxine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  venlafaxine  and  zuclopenthixol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "316",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Venlafaxine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/venlafaxine-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Venlafaxine </title>"
			},
			"rdfs:label": "venlafaxine"
		}
	]
}